Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Garcia-Vega, Yanelda
17  Ergebnisse:
Personensuche X
?
1

Open-label phase I/II clinical trial of SARS-CoV-2 receptor..:

Puga-Gómez, Rinaldo ; Ricardo-Delgado, Yariset ; Rojas-Iriarte, Chaumey...
International Journal of Infectious Diseases.  126 (2023)  - p. 164-173 , 2023
Link: https://doi.org/10.1016/..
 
?
2

Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERA..:

Eugenia-Toledo-Romaní, María ; Verdecia-Sánchez, Leslyhana ; Rodríguez-González, Meiby...
Vaccine.  40 (2022)  31 - p. 4220-4230 , 2022
Link: https://doi.org/10.1016/..
 
?
3

Safety and immunogenicity of anti-SARS-CoV-2 heterologous s..:

Toledo-Romani, María Eugenia ; García-Carmenate, Mayra ; Verdecia-Sánchez, Leslyhana...
Med.  3 (2022)  11 - p. 760-773.e5 , 2022
Link: https://doi.org/10.1016/..
 
?
4

Pharmacokinetic and pharmacodynamic characterization of a n..:

for the CIGB-128-A Study Group ; García-García, Idrian ; Hernández-González, Ignacio...
BMC Pharmacology and Toxicology.  17 (2016)  1 - p. , 2016
Link: https://doi.org/10.1186/..
 
?
5

Pharmacokinetic and pharmacodynamic characterization of a n..:

García-Vega, Yanelda ; García-García, Idrian ; Collazo-Caballero, Sonia E...
BMC Pharmacology and Toxicology.  13 (2012)  1 - p. , 2012
Link: https://doi.org/10.1186/..
 
?
6

Treatment of advanced, recurrent, resistant to previous tre..:

Anasagasti-Angulo, Lorenzo ; Garcia-Vega, Yanelda ; Barcelona-Perez, Silvia..
BMC Cancer.  9 (2009)  1 - p. , 2009
Link: https://doi.org/10.1186/..
 
?
7

Bioequivalence of two recombinant granulocyte colony-stimul..:

Hernández-Bernal, Francisco ; García-García, Idrian ; González-Delgado, Carlos A....
Biopharmaceutics & Drug Disposition.  26 (2005)  4 - p. 151-159 , 2005
Link: https://doi.org/10.1002/..
 
?
8

Pharmacokinetic and pharmacodynamic characterization of a n..:

García-García, Idrian ; Hernández-González, Ignacio ; Díaz-Machado, Alina...
http://www.biomedcentral.com/2050-6511/17/58.  , 2016
Link: http://www.biomedcentral..
 
?
9

Pharmacokinetic and pharmacodynamic characterization of a n..:

García-Vega, Yanelda ; García-García, Idrian ; Collazo-Caballero, Sonia E...
http://www.biomedcentral.com/2050-6511/13/20.  , 2012
Link: http://www.biomedcentral..
 
?
10

Treatment of advanced, recurrent, resistant to previous tre..:

Lopez-Saura Pedro ; Barcelona-Perez Silvia ; Garcia-Vega Yanelda..
http://www.biomedcentral.com/1471-2407/9/262.  , 2009
Link: https://doi.org/10.1186/..
 
?
11

Treatment of advanced, recurrent, resistant to previous tre..:

Anasagasti-Angulo, Lorenzo ; Garcia-Vega, Yanelda ; Barcelona-Perez, Silvia..
http://www.biomedcentral.com/1471-2407/9/262.  , 2009
Link: http://www.biomedcentral..
 
?
12

Respuesta clínica del tratamiento con HerberFERON( en pacie..:

Irene Rojas Rondón ; Lázaro Vigoa Aranguren ; Yanelda Garcìa Vega..
http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21762021000100013&tlng=es.  , 2021
Link: https://doaj.org/article..
 
?
13

Seguridad del HeberFERON( en pacientes con carcinoma basal ..:

Irene Rojas Rondón ; Lázaro Vigoa Aranguren ; Yanelda García Vega..
http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21762021000100011&tlng=es.  , 2021
Link: https://doaj.org/article..
 
?
14

Seguridad de la aplicación intravenosa del cigb-300 en paci..:

Julio D Fernández Águila ; Yanelda García Vega ; Rosa Oliday Ríos Jiménez...
http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892016000200008&lng=en&tlng=en.  ,
Link: https://doaj.org/article..
 
?
15

Open-label phase I/II clinical trial of SARS-CoV-2 receptor..:

Rinaldo Puga-Gómez ; Yariset Ricardo-Delgado ; Chaumey Rojas-Iriarte...
http://www.sciencedirect.com/science/article/pii/S1201971222006014.  , 2023
Link: https://doi.org/10.1016/..
 
1-15